A Phase 1/2 interventional study of Infigratinib in Advanced Solid Tumor, CNS Tumor and Recurrent WHO Grade II Glioma, sponsored by Helsinn Healthcare SA. Withdrawn at 10 sites in 3 countries. Open to participants aged 3 Years and older. Per ClinicalTrials.gov, last updated 2023-02-23.
Sponsored by Helsinn Healthcare SA · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 547 studies in Central Nervous System Neoplasms with a site in United States — 46 open to participants now, 74 under way, 3 of them phase 3. Central Nervous System Neoplasms · United States.
Among the 547 studies in Central Nervous System Neoplasms with a site in United States, this one is the 389th largest by enrollment of the 399 interventional ones that give a count, is one of 13 that started in 2021, is one of 70 in phase 1/2, and was the 503rd registered.
699 studies on the registry are indexed under Central Nervous System Neoplasms; 66 are open to participants now.
Browse Central Nervous System Neoplasms studies →46 of the 547 studies in Central Nervous System Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Neonc Technologies, Inc. · Sites in United States
Ages 5–18
BrainChild Bio, Inc · Sites in United States
Ages 1–26
Robbie Majzner · Sites in United States
Ages 2–21
University of California, Irvine · Sites in United States
Ages 18+
National Institute of Neurological Disorders and Stroke (NINDS) · Sites in United States
Ages 18–99
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 57 Central Nervous System Neoplasms studies recruiting now, 35 (61%) set no upper age limit and 19 (33%) stop at 75 or younger; 35 take children under 18; 6 take healthy volunteers.
This study: 3 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
547 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 256 · Phase 2 241 · Phase 3 22 · Phase 4 1
First in 1989; this study’s year is marked. 13 started in 2021.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 31 across the 399 interventional studies, 109 across the 68 observational. Of the 436 that completed or were terminated, 109 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
61 of 547 have an industry lead sponsor. The 10 most frequent:
Helsinn Healthcare SA is the lead sponsor of 32 studies on the registry; 1 is open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.
Helsinn Healthcare SA has 1 study filed under Central Nervous System Neoplasms — fewer than ten, so there is no comparison to draw.
23 of the studies in Central Nervous System Neoplasms with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00978458Phase 3Eastern Cooperative Oncology GroupRadiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma | 2026-12-31 |
| NCT05664243In8bio Inc.A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma | 2026-12 |
| NCT05386108Stemline Therapeutics, Inc.Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer | 2026-12 |
| NCT05425004Baptist Health South FloridaCabozantinib for Patients With Recurrent or Progressive Meningioma | 2026-12 |
| NCT05762419Columbia UniversityFUS Etoposide for DMG | 2026-12 |
Add all 23 to your calendar (.ics) → With an account.
Among the 547 studies in Central Nervous System Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The phase 1b study is aimed at determining the pediatric recommended phase 2 dose (RP2D) of Infigratinib.
The phase 2 study will evaluate efficacy and safety of infigratinib.
Phase 1b:
Pediatric subjects with advanced solid and CNS tumors or recurrent or progressive Low-Grade Glioma with selected FGFR1-3 alterations will follow a standard dose escalation, in 3 dose levels, to determine the pediatric recommended Phase 2 dose (RP2D) and to assess the safety.
Dose escalation decisions will be assessed through three dose level cohorts.
Phase 2:
To evaluate the efficacy and safety in Pediatric and adult subjects with LGG with selected FGFR1-3 alterations (including subjects who received infigratinib at the RP2D).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Phase 1b:
Confirmed diagnosis of one of the following:
Phase 2 at screening:
Phase 1b/2 (all subjects) at screening:
Sex and /Barrier Requirements
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Generic name: infigratinib. Dosage forms: 18mg and 25mg sprinkle capsules and 25mg, 75mg, 100mg capsules. Phase 1b Three dose levels escalation until RP2D is determined. Phase 2 * Pediatric patients: dose defined in the phase 1b (RP2D); * Adults: 125 mg. Frequency: once daily for 21 days in each 28-day treatment cycle. Duration: Treatment duration will last up to 26 cycles unless progression, death or unacceptable toxicity occur.
Drug: Infigratinib
Hard gelatin capsules for oral use
Also known as: BGJ398
Phase 1b Dose Limiting Toxicity (DLT) rate
An adverse event (AE) or abnormal laboratory value that are not clearly due to the underlying disease or extraneous causes, including those AEs and abnormal laboratory values that result in a failure to meet the criteria for re-treatment.
Time frame: 28 days
Phase 2 Objective Response Rate (ORR) by Blinded Independent Central Review (BICR)
The proportion of subjects who achieve a confirmed complete response (CR), confirmed partial response (PR), or confirmed minor response (MR) for subjects with LGG. For other subjects, ORR is defined as proportion of subjects who achieve a confirmed CR or confirmed PR.
Time frame: Up to 24 months
Phase 1b Pharmacokinetics (PK): Cmax
The maximum observed plasma concentration after drug administration (defined as the 2-hour post-dose concentration)
Time frame: Up to 24 months
Phase 1b Pharmacokinetics (PK): AUC
Area under the plasma concentration-time curve
Time frame: Up to 24 months
Phase 1b Pharmacokinetics (PK): T1/2
Apparent terminal Half-Life
Time frame: Up to 24 months
Phase 1b Pharmacokinetics (PK): Tmax
Peak time
Time frame: Up to 24 months
Phase 1b Pharmacokinetics (PK): CL/F
Apparent clearance Day1
Time frame: Up to 24 months
Phase 1b Pharmacokinetics (PK): Vz/F
Apparent volume of distribution
Time frame: Up to 24 months
Phase 1b Best Overall Response (BOR) assessed by Investigator
The best response recorded from the start of the study treatment until the end of treatment taking into account any requirement for confirmation.
Time frame: Up to 24 months
Phase 1b Disease Control Rate (DCR) assessed by Investigator
The proportion of subjects with a Best Overall Response (BOR) of complete response (CR), partial response (PR), minor response (MR) or standard deviation (SD) for subjects with LGG. For other subjects, DCR is defined as the proportion of subjects with a BOR of CR, PR or SD.
Time frame: Up to 24 months
Phase 1b Objective Response Rate (ORR) assessed by Investigator
Time frame: Up to 24 months
Phase 1b Duration of Response (DOR) assessed by Investigator
The time from first documentation of objective response (partial response (PR), complete response (CR), minor response (MR)) to first documentation of PD or death due to any cause, whichever occurs first.
Time frame: Up to 24 months
Phase 1b Time to Response (TTR) assessed by Investigator
The time from the date of the start of the treatment to the date of the first documented objective response (partial response (PR), complete response (CR), minor response (MR)) which is subsequently confirmed.
Time frame: Up to 24 months
Phase 1b Progression Free Survival (PFS) assessed by Investigator
The time from the date of the start of treatment to the date of the first documented progression or death due to any cause, whichever is earlier.
Time frame: Up to 24 months
Post-treatment termination Phase 1b Progression Free Survival (PFS) assessed by Investigator
PFS after treatment termination is the time from the date of treatment interruption for any reason excluding progression disease (PD) to the date of the first documented progression or death due to any cause, whichever is earlier.
Time frame: After treatment termination up to progression disease (PD), assessed for further 24 months
Phase 1b Best change in tumor size assessed by Investigator
The minimum change from baseline in the sum of diameters of target lesions.
Time frame: Up to 24 months
Phase 2 Duration of Response (DOR) assessed by blinded independent central review (BICR)
Time frame: Up to 24 months
Phase 2 Time to Response (TTR) assessed by blinded independent central review (BICR)
Time frame: Up to 24 months
Phase 2 Progression Free survival (PFS) assessed by blinded independent central review (BICR)
Time frame: 6 months from treatment initiation
Phase 2 Progression Free survival (PFS) assessed by blinded independent central review (BICR)
Time frame: 12 months from treatment initiation
Phase 2 Progression Free survival (PFS) assessed by blinded independent central review (BICR)
Time frame: 24 months from treatment initiation
Post-treatment termination Phase 2 Progression Free survival (PFS) assessed by blinded independent central review (BICR)
Time frame: After treatment termination up to progression disease (PD), assessed for further 24 months
Phase 2 Overall Survival (OS)
Overall Survival (OS) is defined as the time from the date of start of treatment to the date of death due to any cause.
Time frame: 12 months
Phase 2 Overall Survival (OS)
Time frame: 24 months
Phase 2 Best Overall Response (BOR) assessed by blinded independent central review (BICR)
Time frame: Up to 24 months
Phase 2 Disease Control Rate (DCR) assessed by blinded independent central review (BICR)
Time frame: Up to 24 months
Phase 2 Best change in tumor size assessed by blinded independent central review (BICR)
Time frame: Up to 24 months
Phase 2 Best Overall Response (BOR) assessed by Investigator
Time frame: Up to 24 months
Phase 2 Disease Control Rate (DCR) assessed by Investigator
Time frame: Up to 24 months
Phase 2 Objective Response Rate (ORR) assessed by Investigator
Time frame: Up to 24 months
Phase 2 Duration of Response (DOR) assessed by Investigator
Time frame: Up to 24 months
Phase 2 Time to Response (TTR) assessed by Investigator
Time frame: Up to 24 months
Phase 2 Progression Free Survival (PFS) assessed by Investigator
Time frame: Up to 24 months
Phase 2 Best change in tumor size assessed by Investigator
Time frame: Up to 24 months
Post-treatment termination Phase 2 Progression Free Survival (PFS) assessed by Investigator
Time frame: After treatment termination up to progression disease (PD), assessed for further 24 months
Phase 1b Incidence/severity of Adverse Events (AEs)
Number of patients who experienced AEs to assess the safety and tolerability of infigratinib in subjects with recurrent or progressive LGG.
Time frame: Up to 30 days after treatment termination
Phase 2 Incidence/severity of Adverse Events (AEs)
Time frame: Up to 30 days after treatment termination
Phase 1b Incidence/severity of Serious Adverse Events (SAEs)
Number of patients who experienced SAEs to assess the safety and tolerability of infigratinib in subjects with recurrent or progressive LGG.
Time frame: Up to 30 days after treatment termination
Phase 2 Incidence/severity of Serious Adverse Events (SAEs)
Time frame: Up to 30 days after treatment termination
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2021 to primary completion in Dec 2022, 14 months.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Infigratinib
Central Nervous System Neoplasms →